Abstract
The influence of pentoxifylline (11-18 mg/kg orally, Trental 400) on impaired hemorheologic conditions has been investigated in a total of 73 patients with CVI. Throughout a treatment period of 4 weeks, there was a significant improvement in red cell behavior and a significant inhibition of increased platelet aggregation; moreover, a fall in plasma fibrinogen and of blood viscosity has also been observed.
MeSH terms
-
Adenosine Diphosphate / antagonists & inhibitors
-
Blood Viscosity
-
Cerebrovascular Disorders / blood
-
Cerebrovascular Disorders / drug therapy*
-
Epinephrine / antagonists & inhibitors
-
Erythrocytes / physiology
-
Female
-
Fibrinogen / analysis
-
Humans
-
Male
-
Middle Aged
-
Pentoxifylline / therapeutic use*
-
Platelet Aggregation / drug effects
-
Rheology
-
Theobromine / analogs & derivatives*
Substances
-
Adenosine Diphosphate
-
Fibrinogen
-
Theobromine
-
Pentoxifylline
-
Epinephrine